You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ALUPENT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Alupent patents expire, and when can generic versions of Alupent launch?

Alupent is a drug marketed by Boehringer Ingelheim and is included in five NDAs.

The generic ingredient in ALUPENT is metaproterenol sulfate. There are six drug master file entries for this compound. Additional details are available on the metaproterenol sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Alupent

A generic version of ALUPENT was approved as metaproterenol sulfate by GENUS on July 22nd, 1992.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALUPENT?
  • What are the global sales for ALUPENT?
  • What is Average Wholesale Price for ALUPENT?
Summary for ALUPENT
US Patents:0
Applicants:1
NDAs:5
Raw Ingredient (Bulk) Api Vendors: 39
Patent Applications: 3,796
DailyMed Link:ALUPENT at DailyMed
Drug patent expirations by year for ALUPENT

US Patents and Regulatory Information for ALUPENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim ALUPENT metaproterenol sulfate AEROSOL, METERED;INHALATION 016402-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SOLUTION;INHALATION 017659-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SOLUTION;INHALATION 018761-002 Oct 10, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SOLUTION;INHALATION 018761-001 Jun 30, 1983 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SYRUP;ORAL 017571-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALUPENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim ALUPENT metaproterenol sulfate SYRUP;ORAL 017571-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate AEROSOL, METERED;INHALATION 016402-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SOLUTION;INHALATION 017659-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate SOLUTION;INHALATION 018761-001 Jun 30, 1983 ⤷  Sign Up ⤷  Sign Up
Boehringer Ingelheim ALUPENT metaproterenol sulfate TABLET;ORAL 015874-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ALUPENT

See the table below for patents covering ALUPENT around the world.

Country Patent Number Title Estimated Expiration
Netherlands 120608 ⤷  Sign Up
African Intellectual Property Organization (OAPI) 1090 ⤷  Sign Up
United Kingdom 920623 ⤷  Sign Up
Switzerland 410008 Verfahren zur Herstellung neuer Aminoalkohole ⤷  Sign Up
France 1466215 Procédé pour la préparation de nouveaux amino-alcools ⤷  Sign Up
France 922 ⤷  Sign Up
Switzerland 410009 Verfahren zur Herstellung neuer Aminoalkohole ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.